AstraZeneca partners with Oracle for AI-driven clinical trials

SENSEX 73,852.90

 -876.37

NIFTY 22,888.95

 -257.20

CRUDEOIL 9,462.00

+ 68.00

GOLD 147,308.00

 -610.00

SILVER 209,850.00

 -1,337.00

SENSEX 73,852.90

 -876.37

NIFTY 22,888.95

 -257.20

NIFTY 22,888.95

 -257.20

CRUDEOIL 9,462.00

+ 68.00

CRUDEOIL 9,462.00

+ 68.00

GOLD 147,308.00

 -610.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

AstraZeneca and Oracle launch AI-powered real-world data trials in Abu Dhabi, accelerating recruitment and safety monitoring across multiple diseases

By Reuters

Updated - October 20, 2026 at 01:29 PM.

AstraZeneca said on Tuesday that it is working ​with Oracle to use AI ‌and real-world data to identify eligible ​patients for clinical trials ⁠and monitor safety signals, among other measures, as the drugmaker looks to improve ‌clinical research.

• The collaboration will combine AstraZeneca's drug development ‌expertise with Oracle's AI ‌and ⁠healthcare data capabilities to support ⁠patient matching and research
• Initial work will focus on cancer, cardiovascular, respiratory, immunology ​and rare ‌diseases, and could also support earlier diagnosis of serious diseases
• The first project will support hypertension ‌research in Abu Dhabi in ​partnership with UAE-based healthcare firm M42
• Patient recruitment ⁠remains one of the biggest challenges in clinical research, with delayed ‌enrolment often extending trial timelines and increasing development costs
• Incorrect trial designs have also hurt AstraZeneca in the past, with delays on its breast cancer ‌drug and nerve disorder treatment failure ​causing some worries
• AstraZeneca is seeking to expand its ⁠medicine portfolio as it targets over $80 ⁠billion in annual revenue by 2030, and works to address ‌industry bottlenecks in drug development

Published on October 20, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers